ATG10: A Potential Drug Target and Biomarker for Neurological Disorders

Target Name: ATG10

NCBI ID: G83734

ATG10

ATG10: A Potential Drug Target and Biomarker for Neurological Disorders

ATG10 (DKFZp586I0418) is a protein that is expressed in various tissues of the body, including the brain. It is a member of the ATG/SPOP gene family, which is involved in the regulation of cell signaling pathways. ATG10 has been shown to play a role in the development and progression of various neurological and psychiatric disorders, including Alzheimer's disease and schizophrenia. As a result, ATG10 has generated a lot of interest as a potential drug target or biomarker.

ATG10 is a 21-kDa protein that is expressed in the brain and other tissues of the body. It is a member of the ATG/SPOP gene family, which is characterized by the presence of a specific transcription factor binding site (TBP) in its coding region. The TBP is a protein that is known to play a role in the regulation of cell signaling pathways, and it is thought to recruit other proteins to the same site in order to facilitate their interaction and regulate their activity.

ATG10 is involved in a number of different cellular processes in the brain, including the regulation of neurotransmitter signaling, the development and maintenance of synapses, and the regulation of the cell cycle. It has been shown to play a role in the development and progression of various neurological and psychiatric disorders, including Alzheimer's disease and schizophrenia.

One of the most promising aspects of ATG10 is its potential as a drug target. The development of new treatments for neurological and psychiatric disorders is a major goal of modern medicine, and ATG10 is seen as a promising target for these diseases. Because ATG10 is involved in the regulation of a wide range of cellular processes, it is likely that it can be targeted by small molecules that can modulate its activity. This has led to a great deal of interest in the development of compounds that can specifically interact with ATG10 and enhance its activity.

In addition to its potential as a drug target, ATG10 is also a potential biomarker for the diagnosis and progression of neurological and psychiatric disorders. The use of biomarkers is a growing trend in the field of disease diagnosis and treatment, and ATG10 could be used as a biomarker for a variety of disorders. For example, it has been shown to be expressed in the brains of individuals with Alzheimer's disease, and levels of ATG10 have been correlated with the severity of the disease. This suggests that ATG10 could be used as a diagnostic biomarker for Alzheimer's disease.

Another potential application of ATG10 is its use as a target for small molecules that can modulate its activity and serve as therapeutic compounds. The development of new drugs that can specifically modulate the activity of ATG10 is an exciting area of 鈥嬧?媟esearch, and has the potential to lead to the development of new treatments for a wide range of neurological and psychiatric disorders.

In conclusion, ATG10 is a protein that is expressed in various tissues of the body and is involved in the regulation of a wide range of cellular processes in the brain. Its potential as a drug target or biomarker for neurological and psychiatric disorders is highly promising, and the development of new treatments based on ATG10 is an exciting area of 鈥嬧?媟esearch. Further studies are needed to fully understand the role of ATG10 in the development and progression of these disorders and to develop new treatments based on it.

Protein Name: Autophagy Related 10

Functions: E2-like enzyme involved in autophagy. Acts as an E2-like enzyme that catalyzes the conjugation of ATG12 to ATG5. ATG12 conjugation to ATG5 is required for autophagy. Likely serves as an ATG5-recognition molecule. Not involved in ATG12 conjugation to ATG3 (By similarity). Plays a role in adenovirus-mediated cell lysis

The "ATG10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATG10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets